Immunohistochemical detection of S100A1 in the postmortem diagnosis of acute myocardial infarction

Diagnostic Pathology

Bin Cong¹  Chunling Ma¹  Yingmin Li¹  Jianye Huang¹  Ying Yang¹  Haitao Bi¹ 

[1] Department of Forensic Medicine, Hebei Medical University, No. 361 Zhongshan Road, Shijiazhuang, Hebei 050017, China

关键词: Enzyme-linked immunosorbent assay;    Immunohistochemistry;    S100A1;    Acute myocardial infarction;   

Others  :  806914
DOI  :  10.1186/1746-1596-8-84

 received in 2013-03-24, accepted in 2013-05-08,  发布年份 2013

【 摘 要 】

Background

Sudden cardiac death resulting from acute myocardial infarction (AMI) constitutes a significant percentage of the caseload for forensic and clinical pathologists. When sudden death occurs at an early stage (<6 h), pathologists experience difficulty in the postmortem diagnosis of AMI. Because of the specific tissue distribution of S100A1 and its relationship with acute ischemic heart disease, this study aimed to evaluate the performance of S100A1 in the postmortem diagnosis of AMI.

Methods

We constructed a rat model of AMI through permanent ligation of the left anterior descending coronary artery (LAD) to investigate the depletion of S100A1 from ischemic cardiomyocytes by immunohistochemistry and measuring S100A1 plasma concentrations by enzyme-linked immunosorbent assay at varying post-infarction intervals. In addition, immunohistochemical staining of S100A1 for definite infarction, suspected early infarction, and in normal human hearts, was also performed to test its practical feasibility for postmortem diagnosis of AMI at an early stage.

Results

As early as 15 min after ligation of the LAD, depletion of S100A1 was observed in ischemic cardiomyocytes, and S100A1 plasma concentration was also significantly higher than that of the sham-operated group (P < 0.001). With continuation of the occlusion time, the depleted areas of S100A1 further expanded and S100A1 plasma concentrations further increased. For autopsy material, all human cases of definite myocardial infarction and suspected early infarction showed well-defined areas without S100A1 staining. None of the normal human cases showed diffuse depletion of S100A1.

Conclusion

Our results suggest that immunohistochemical detection of S100A1 is useful for the postmortem diagnosis of AMI at an early stage.

Virtual slides

The virtual slide(s) for this article can be found here:

http://www.diagnosticpathology.diagnomx.eu/vs/4366650979519818 webcite

【 授权许可】

   
2013 Bi et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Hua W, Zhang LF, Wu YF, Liu XQ, Guo DS, Zhou HL, Gou ZP, Zhao LC, Niu HX, Chen KP, Mai JZ, Chu LN, Zhang S: Incidence of sudden cardiac death in China: analysis of 4 regional populations. J Am Coll Cardiol 2009, 54:1110-1118.
• [2]de la Grandmaison GL: Is there progress in the autopsy diagnosis of sudden unexpected death in adults? Forensic Sci Int 2006, 156:138-144.
• [3]Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD: Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial: Third universal definition of myocardial infarction. Eur Heart J 2012, 33:2551-2567.
• [4]Campobasso CP, Dell’Erba AS, Addante A, Zotti F, Marzullo A, Colonna MF: Sudden cardiac death and myocardial ischemia indicators: a comparative study of four immunohistochemical markers. Am J Forensic Med Pathol 2008, 29:154-161.
• [5]Zhu BL, Tanaka S, Ishikawa T, Zhao D, Li DR, Michiue T, Quan L, Maeda H: Forensic pathological investigation of myocardial hypoxia-inducible factor-1 alpha, erythropoietin and vascular endothelial growth factor in cardiac death. Leg Med 2008, 10:11-19.
• [6]Yang TT, Weng SF, Zheng N, Pan QH, Cao HL, Liu L, Zhang HD, Mu da W: Histopathology mapping of biochemical changes in myocardial infarction by Fourier transform infrared spectral imaging. Forensic Sci Int 2011, 207:e34-39.
• [7]Most P, Remppis A, Pleger ST, Katus HA, Koch WJ: S100A1: a novel inotropic regulator of cardiac performance. Transition from molecular physiology to pathophysiological relevance. Am J Physiol Regul Integr Comp Physiol 2007, 293:R568-577.
• [8]Schaub MC, Heizmann CW: Calcium, troponin, calmodulin, S100 proteins: from myocardial basics to new therapeutic strategies. Biochem Biophys Res Commun 2008, 369:247-264.
• [9]Remppis A, Greten T, Schäfer BW, Hunziker P, Erne P, Katus HA, Heizmann CW: Altered expression of the Ca(2+)-binding protein S100A1 in human cardiomyopathy. Biochim Biophys Acta 1996, 1313:253-257.
• [10]Kato K, Kimura S: S100ao (alpha alpha) protein is mainly located in the heart and striated muscles. Biochim Biophys Acta 1985, 842:146-150.
• [11]Kiewitz R, Lyons GE, Schäfer BW, Heizmann CW: Transcriptional regulation of S100A1 and expression during mouse heart development. Biochim Biophys Acta 2000, 1498:207-219.
• [12]Lefranc F, Decaestecker C, Brotchi J, Heizmann CW, Dewitte O, Kiss R, Mijatovic T: Co-expression/co-location of S100 proteins (S100B, S100A1 and S100A2) and protein kinase C (PKC-beta, -eta and -zeta) in a rat model of cerebral basilar artery vasospasm. Neuropathol Appl Neurobiol 2005, 31:649-660.
• [13]Most P, Seifert H, Gao E, Funakoshi H, Völkers M, Heierhorst J, Remppis A, Pleger ST, DeGeorge BR Jr, Eckhart AD, Feldman AM, Koch WJ: Cardiac S100A1 protein levels determine contractile performance and propensity towards heart failure after myocardial infarction. Circulation 2006, 114:1258-1268.
• [14]Kraus C, Rohde D, Weidenhammer C, Qiu G, Pleger ST, Voelkers M, Boerries M, Remppis A, Katus HA, Most P: S100A1 in cardiovascular health and disease: closing the gap between basic science and clinical therapy. J Mol Cell Cardiol 2009, 47:445-455.
• [15]Usui A, Kato K, Sasa H, Minaguchi K, Abe T, Murase M, Tanaka M, Takeuchi E: S-100ao protein in serum during acute myocardial infarction. Clin Chem 1990, 36:639-641.
• [16]Kiewitz R, Acklin C, Minder E, Huber PR, Schäfer BW, Heizmann CW: S100A1, a new marker for acute myocardial ischemia. Biochem Biophys Res Commun 2000, 274:865-871.
• [17]Meng X, Ming M, Wang E: Heart fatty acid binding protein as a marker for postmortem detection of early myocardial damage. Forensic Sci Int 2006, 160:11-16.
• [18]Lie JT, Holley KE, Kampa WR, Titus JL: New histochemical method for morphologic diagnosis of early stages of myocardial ischemia. Mayo Clin Proc 1971, 46:319-327.
• [19]Chugh SS, Reinier K, Teodorescu C, Evanado A, Kehr E, Al Samara M, Mariani R, Gunson K, Jui J: Epidemiology of sudden cardiac death: clinical and research implications. Prog Cardiovasc Dis 2008, 51:213-228.
• [20]Jia Wei1, Jiarong T, Liming X, Xinshan C, Dao Wen W: A case of Arrhythmogenic right ventricular cardiomyopathy without arrhythmias. Diagn Pathol 2012, 7:67. BioMed Central Full Text
• [21]Fabio D-G, Vincenzo A: Ostial plication: a rarely reported cause of sudden death. Diagn Pathol 2010, 5:15. BioMed Central Full Text
• [22]De-Giorgio1 F, Grassi1 VM, Vetrugno1 G, Vincenzo A: Sudden death in a young female with an under-recognised coronary anomaly. Diagn Pathol 2013, 8:41. BioMed Central Full Text
• [23]Bello S, Neri M, Riezzo I, Othman M, Turillazzi E, Fineschi V: Cardiac beriberi: morphological findings in two fatal cases. Diagn Pathol 2011, 6:8. BioMed Central Full Text
• [24]Chopra N, Knollmann BC: Genetics of Sudden Cardiac Death Syndromes. Curr Opin Cardiol 2011, 26:196-203.
• [25]Mair J: Tissue release of cardiac markers: from physiology to clinical applications. Clin Chem Lab Med 1999, 37:1077-1084.
• [26]Hansen SH, Rossen K: Evaluation of cardiac troponin I immunoreaction in autopsy hearts: a possible marker of early myocardial infarction. Forensic Sci Int 1999, 99:189-196.